Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
HEPATITIS TUTORING PART 2 BY ALAINA DARBY BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1 and is started on peginterferon + ribavirin. When should you assess therapy? a. b. c. d. 4 weeks 12 weeks 24 weeks 48 weeks BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1 and is started on peginterferon + ribavirin. At 12 weeks, he has the targeted virological response. What is the shortest duration for therapy to be continued? a. b. c. d. 4 weeks 12 weeks 24 weeks 48 weeks BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1 and is started on peginterferon + ribavirin. Which of the following DAA’s would be most likely included with this regimen? a. b. c. d. Dasabuvir Ombitasvir Grazoprevir Sofosbuvir BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1. For DAA treatment, which of the following classes would be best if you expect resistance to be an issue? a. b. c. d. PI’s NS5Ai’s NS5B NUCi’s NS5B non-NUCi’s BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1. For DAA treatment, which of the following drugs would be best if you expect resistance to be an issue? a. b. c. d. Dasabuvir Ombitasvir Grazoprevir Sofosbuvir AGENTS PI’s NS5Ai’s NS5B NUCi’s NS5B non-NUCi’s MOA Protein transport/ processing Potency High High Intermediate Intermediate GT coverage Limited Multiple High Low Barrier to resistance Low Low High High RNA replication and assembly BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1. For DAA treatment, which of the following drugs would be most likely to complicate treatment if he also has HIV? a. b. c. d. Dasabuvir Ombitasvir Grazoprevir Sofosbuvir BK is a 62 yo WM who presents to you complaining of abdominal pain and dark urine. He is determined to have HCV genotype 1. Assuming that he is taking all of the following medications, which would you change/discontinue should you start Harvoni? a. b. c. d. Omeprazole Clopidogrel Metformin Lisinopril Your patient is a heavy drinker who has an elevated INR, AST/ALT are within normal limits, SCr is 2.4, and he has also been diagnosed with HCV. Which of the following would be preferred? a. b. c. d. Ledipasvir/sofosbuvir Paritaprevir/ritonavir/ombitasvir + dasabuvir Daclatasvir/sofosbuvir Elbasvir/grazoprevir Your patient has been diagnosed with GT 2. Which of the following should he receive? a. b. c. d. Ledipasvir/sofosbuvir Paritaprevir/ritonavir/ombitasvir + dasabuvir Daclatasvir/sofosbuvir Elbasvir/grazoprevir APPROVED REGIMENS BY GENOTYPE/DAA 1 Lepidasvir/sofosbuvir X Daclatasvir/sofosbuvir X Paritaprevir/ritonavir/ ombitasvir Paritaprevir/ritonavir/ ombitasvir + dasabuvir 2 X 3 4 5/6 X X X X X Your patient has recently had a cardiac stent placed and is taking clopidogrel. Which of the following should be avoided? a. b. c. d. Ledipasvir/sofosbuvir Paritaprevir/ritonavir/ombitasvir + dasabuvir Daclatasvir/sofosbuvir Elbasvir/grazoprevir WATCH OUT! … FOR DRUG INTERACTIONS CYP & pgp… Daclatasvir, Elbasvir, Grazoprevir Pgp only… Ledipasvir, Sofosbuvir